Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CPIX's Cash to Debt is ranked higher than
99% of the 1159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.17 vs. CPIX: No Debt )
CPIX' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: No Debt

Equity to Asset 0.85
CPIX's Equity to Asset is ranked higher than
92% of the 1084 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. CPIX: 0.85 )
CPIX' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.91
Current: 0.85

0.42
0.91
Interest Coverage 53.12
CPIX's Interest Coverage is ranked higher than
62% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. CPIX: 53.12 )
CPIX' s 10-Year Interest Coverage Range
Min: 3.08   Max: 122.47
Current: 53.12

3.08
122.47
F-Score: 8
Z-Score: 6.11
M-Score: -2.65
WACC vs ROIC
14.19%
8.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.64
CPIX's Operating margin (%) is ranked higher than
74% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. CPIX: 9.64 )
CPIX' s 10-Year Operating margin (%) Range
Min: -11.87   Max: 23.96
Current: 9.64

-11.87
23.96
Net-margin (%) 6.57
CPIX's Net-margin (%) is ranked higher than
73% of the 1110 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. CPIX: 6.57 )
CPIX' s 10-Year Net-margin (%) Range
Min: -6.57   Max: 24.72
Current: 6.57

-6.57
24.72
ROE (%) 3.02
CPIX's ROE (%) is ranked higher than
65% of the 1139 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.62 vs. CPIX: 3.02 )
CPIX' s 10-Year ROE (%) Range
Min: -2.55   Max: 50.74
Current: 3.02

-2.55
50.74
ROA (%) 2.63
CPIX's ROA (%) is ranked higher than
70% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.52 vs. CPIX: 2.63 )
CPIX' s 10-Year ROA (%) Range
Min: -2.26   Max: 24.03
Current: 2.63

-2.26
24.03
ROC (Joel Greenblatt) (%) 67.54
CPIX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. CPIX: 67.54 )
CPIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46.2   Max: 1632.74
Current: 67.54

-46.2
1632.74
Revenue Growth (3Y)(%) -6.10
CPIX's Revenue Growth (3Y)(%) is ranked higher than
56% of the 940 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. CPIX: -6.10 )
CPIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.1   Max: 47.5
Current: -6.1

-7.1
47.5
EBITDA Growth (3Y)(%) -16.00
CPIX's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 851 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. CPIX: -16.00 )
CPIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16   Max: 102.7
Current: -16

-16
102.7
EPS Growth (3Y)(%) -20.60
CPIX's EPS Growth (3Y)(%) is ranked higher than
59% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. CPIX: -20.60 )
CPIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6   Max: 34.2
Current: -20.6

-20.6
34.2
» CPIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CPIX Guru Trades in Q1 2014

John Rogers 2,663,520 sh (+4.91%)
Jim Simons 95,597 sh (-28.34%)
» More
Q2 2014

CPIX Guru Trades in Q2 2014

John Rogers 2,663,170 sh (-0.01%)
Jim Simons 76,800 sh (-19.66%)
» More
Q3 2014

CPIX Guru Trades in Q3 2014

Jim Simons 84,100 sh (+9.51%)
John Rogers 2,607,251 sh (-2.10%)
» More
Q4 2014

CPIX Guru Trades in Q4 2014

Jim Simons 120,900 sh (+43.76%)
John Rogers 2,085,426 sh (unchged)
John Rogers 2,085,426 sh (unchged)
John Rogers 2,085,426 sh (unchged)
John Rogers 2,085,426 sh (-20.01%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.70
CPIX's P/E(ttm) is ranked higher than
76% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.00 vs. CPIX: 47.70 )
CPIX' s 10-Year P/E(ttm) Range
Min: 12.4   Max: 302.94
Current: 47.7

12.4
302.94
Forward P/E 50.00
CPIX's Forward P/E is ranked higher than
74% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 50.00 )
N/A
PE(NRI) 47.20
CPIX's PE(NRI) is ranked higher than
79% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.20 vs. CPIX: 47.20 )
CPIX' s 10-Year PE(NRI) Range
Min: 12.55   Max: 257.5
Current: 47.2

12.55
257.5
P/B 1.50
CPIX's P/B is ranked higher than
89% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. CPIX: 1.50 )
CPIX' s 10-Year P/B Range
Min: 0.9   Max: 4.84
Current: 1.5

0.9
4.84
P/S 3.19
CPIX's P/S is ranked higher than
69% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.24 vs. CPIX: 3.19 )
CPIX' s 10-Year P/S Range
Min: 1.65   Max: 6.82
Current: 3.19

1.65
6.82
PFCF 35.00
CPIX's PFCF is ranked higher than
85% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3458.60 vs. CPIX: 35.00 )
CPIX' s 10-Year PFCF Range
Min: 12.69   Max: 1432
Current: 35

12.69
1432
POCF 17.39
CPIX's POCF is ranked higher than
88% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.77 vs. CPIX: 17.39 )
CPIX' s 10-Year POCF Range
Min: 11.33   Max: 769
Current: 17.39

11.33
769
EV-to-EBIT 16.12
CPIX's EV-to-EBIT is ranked higher than
89% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.13 vs. CPIX: 16.12 )
CPIX' s 10-Year EV-to-EBIT Range
Min: -16.4   Max: 265.4
Current: 16.12

-16.4
265.4
Shiller P/E 41.40
CPIX's Shiller P/E is ranked higher than
87% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 41.40 )
CPIX' s 10-Year Shiller P/E Range
Min: 16.32   Max: 43.75
Current: 41.4

16.32
43.75
Current Ratio 5.15
CPIX's Current Ratio is ranked higher than
88% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. CPIX: 5.15 )
CPIX' s 10-Year Current Ratio Range
Min: 1.45   Max: 13.23
Current: 5.15

1.45
13.23
Quick Ratio 4.74
CPIX's Quick Ratio is ranked higher than
89% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. CPIX: 4.74 )
CPIX' s 10-Year Quick Ratio Range
Min: 1.38   Max: 12.35
Current: 4.74

1.38
12.35
Days Inventory 460.37
CPIX's Days Inventory is ranked higher than
54% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.39 vs. CPIX: 460.37 )
CPIX' s 10-Year Days Inventory Range
Min: 92.58   Max: 636.33
Current: 460.37

92.58
636.33
Days Sales Outstanding 54.45
CPIX's Days Sales Outstanding is ranked higher than
84% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 90.94 vs. CPIX: 54.45 )
CPIX' s 10-Year Days Sales Outstanding Range
Min: 30.88   Max: 104.9
Current: 54.45

30.88
104.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.80
CPIX's Price/Net Cash is ranked higher than
98% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 2.80 )
CPIX' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 5.81
Current: 2.8

1.37
5.81
Price/Net Current Asset Value 2.40
CPIX's Price/Net Current Asset Value is ranked higher than
98% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 2.40 )
CPIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 4.44
Current: 2.4

1.07
4.44
Price/Tangible Book 1.90
CPIX's Price/Tangible Book is ranked higher than
89% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. CPIX: 1.90 )
CPIX' s 10-Year Price/Tangible Book Range
Min: 1.04   Max: 5.21
Current: 1.9

1.04
5.21
Price/DCF (Projected) 1.50
CPIX's Price/DCF (Projected) is ranked higher than
93% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. CPIX: 1.50 )
CPIX' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 1.34
Current: 1.5

0.7
1.34
Price/Median PS Value 1.20
CPIX's Price/Median PS Value is ranked higher than
80% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. CPIX: 1.20 )
CPIX' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 2.18
Current: 1.2

0.65
2.18
Price/Graham Number 2.00
CPIX's Price/Graham Number is ranked higher than
86% of the 1281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. CPIX: 2.00 )
CPIX' s 10-Year Price/Graham Number Range
Min: 0.8   Max: 4.12
Current: 2

0.8
4.12
Earnings Yield (Greenblatt) 6.30
CPIX's Earnings Yield (Greenblatt) is ranked higher than
87% of the 1155 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. CPIX: 6.30 )
CPIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 76.6
Current: 6.3

0.4
76.6
Forward Rate of Return (Yacktman) -0.10
CPIX's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.86 vs. CPIX: -0.10 )
CPIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.5   Max: 17.4
Current: -0.1

0.5
17.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CBJ.Germany,
Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... May 01 2015
Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results Apr 30 2015
Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results Apr 30 2015
CUMBERLAND PHARMACEUTICALS INC Financials Mar 14 2015
Message From CEO Mar 13 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 09 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 04 2015
Cumberland posts 4Q profit Mar 03 2015
Cumberland posts 4Q profit Mar 03 2015
Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones Mar 03 2015
Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones Mar 03 2015
Cumberland Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Mar 03 2015
Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014 Mar 03 2015
Q4 2014 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close Mar 03 2015
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2014 Financial Results Feb 24 2015
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2014 Financial Results Feb 24 2015
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 13 2015
Cumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban™ (ifetroban) Oral Capsule Feb 11 2015
Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor®... Feb 02 2015
Phase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor®... Feb 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK